These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 10582874

  • 1. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
    Schülin T, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM.
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2873-6. PubMed ID: 10582874
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
    Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR.
    Clin Infect Dis; 1999 Mar; 28(3):689-90. PubMed ID: 10194104
    [No Abstract] [Full Text] [Related]

  • 4. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
    Schaadt RD, Batts DH, Daley-Yates PT, Pawsey SD, Stalker DJ, Zurenko GE.
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):201-4. PubMed ID: 9327249
    [Abstract] [Full Text] [Related]

  • 5. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK.
    Drugs; 2002 Aug; 62(3):425-41. PubMed ID: 11827558
    [Abstract] [Full Text] [Related]

  • 6. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
    Swoboda S, Fritz S, Martignoni ME, Feldhues RA, Hoppe-Tichy T, Buchler MW, Geiss HK.
    J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
    [Abstract] [Full Text] [Related]

  • 7. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 8. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
    Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP.
    Lancet; 2001 Apr 14; 357(9263):1179. PubMed ID: 11323048
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec 14; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 10. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
    Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H.
    Antimicrob Agents Chemother; 2006 Dec 14; 50(12):4217-9. PubMed ID: 16982791
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE, Smith JR, Raut A, Rybak MJ.
    J Antimicrob Chemother; 2016 Jan 14; 71(1):152-5. PubMed ID: 26476277
    [Abstract] [Full Text] [Related]

  • 12. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP, Bierman BC.
    Int J Antimicrob Agents; 2009 Jul 14; 34(1):21-4. PubMed ID: 19243921
    [Abstract] [Full Text] [Related]

  • 13. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
    Johnson AP, Tysall L, Stockdale MV, Woodford N, Kaufmann ME, Warner M, Livermore DM, Asboth F, Allerberger FJ.
    Eur J Clin Microbiol Infect Dis; 2002 Oct 14; 21(10):751-4. PubMed ID: 12415476
    [Abstract] [Full Text] [Related]

  • 14. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
    Luther MK, Arvanitis M, Mylonakis E, LaPlante KL.
    Antimicrob Agents Chemother; 2014 Aug 14; 58(8):4612-20. PubMed ID: 24867993
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK, Kim Y, Park KS, Yang JW, Kim K, Ha NJ.
    J Biochem Mol Biol; 2007 Nov 30; 40(6):881-7. PubMed ID: 18047782
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Jun 30; 56(6):3174-80. PubMed ID: 22470111
    [Abstract] [Full Text] [Related]

  • 17. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature.
    Tan TY, Pitman I, Penrose-Stevens A, Simpson BA, Flanagan PG.
    J Infect; 2000 Jul 30; 41(1):95-7. PubMed ID: 11041712
    [Abstract] [Full Text] [Related]

  • 18. Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.
    Moreillon P, Wilson WR, Leclercq R, Entenza JM.
    Antimicrob Agents Chemother; 2007 May 30; 51(5):1661-5. PubMed ID: 17353251
    [Abstract] [Full Text] [Related]

  • 19. First report of a linezolid- and vancomycin-resistant Enterococcus faecium strain in Korea.
    Bae HG, Sung H, Kim MN, Lee EJ, Koo Lee S.
    Scand J Infect Dis; 2006 May 30; 38(5):383-6. PubMed ID: 16709544
    [Abstract] [Full Text] [Related]

  • 20. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.
    Till M, Wixson RL, Pertel PE.
    Clin Infect Dis; 2002 May 15; 34(10):1412-4. PubMed ID: 11981739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.